Achieving and maintaining long-term optimal improvements in patient-reported symptoms, signs, and quality of life among patients with moderate-to-severe psoriasis treated with guselkumab: 5-year data from VOYAGE 1

被引：0
|
作者：
Griffiths, Christopher E. M. [1 ]
Blauvelt, Andrew [2 ]
Han, Chenglong [3 ]
Fernandez-Penas, Pablo [4 ,5 ]
Adam, David N. [6 ,7 ]
Philipp, Sandra [8 ]
Song, Michael [9 ]
Miller, Megan [9 ]
You, Yin [9 ]
Langley, Richard G. [10 ]
机构：
[1] Univ Manchester, Salford Royal NHS Fdn Trust, NIHR Manchester Biomed Res Ctr, Dermatol Ctr, Manchester, Lancs, England
[2] Oregon Med Res Ctr, Portland, OR USA
[3] Janssen Global Serv LLC, Raritan, NJ USA
[4] Univ Sydney, Sydney, NSW, Australia
[5] Westmead Hosp, Westmead, NSW, Australia
[6] CCA Med Res Corp & Probity Med Res, Ajax, ON, Canada
[7] Prob Med Res, Waterloo, ON, Canada
[8] Charite Univ Med Berlin, Dept Dermatol, Berlin, Germany
[9] Janssen Res & Dev LLC, Raritan, NJ USA
[10] Dalhousie Univ, Halifax, NS, Canada
来源：
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY | 2021年 / 85卷 / 03期
关键词：
D O I：
暂无
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
27043
引用
收藏
页码：AB127 / AB127
页数：1
相关论文
共 50 条
  • [21] Long-term efficacy of ustekinumab in patients with moderate-to-severe psoriasis treated for up to 5 years in the PHOENIX 1 study
    Kimball, A. B.
    Papp, K. A.
    Wasfi, Y.
    Chan, D.
    Bissonnette, R.
    Sofen, H.
    Yeilding, N.
    Li, S.
    Szapary, P.
    Gordon, K. B.
    JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2013, 27 (12) : 1535 - 1545
  • [22] Quality of life and patient-reported symptoms in a Phase 4, real-world study of tildrakizumab in patients with moderate-to-severe psoriasis: Week 28 interim analysis
    Bhatia, Neal
    Heim, Jayme
    Schenkel, Brad
    Vasquez, J. Gabriel
    JOURNAL OF DERMATOLOGICAL TREATMENT, 2023, 34 (01)
  • [23] Long-term effect of achieving PASI90 compared with PASI75 response on patient-reported outcomes in patients with moderate to severe psoriasis
    Ryan, Caitriona
    Sundaram, Murali
    Yang, Min
    Goyal, Ravi
    Signorovitch, James
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2016, 74 (05) : AB259 - AB259
  • [24] Fatigue in prostate cancer patients treated with external beam radiotherapy: A prospective 5-year long-term patient-reported evaluation
    Fransson, Per
    JOURNAL OF CANCER RESEARCH AND THERAPEUTICS, 2010, 6 (04) : 516 - 520
  • [25] Long-term maintenance of improvements in patient-reported functioning, quality-of-life, and pain outcomes for moderate-to-severe chronic pain patients receiving continuous treatment of Butrans® (buprenorphine) Transdermal System (BTDS)
    Yarlas, A.
    Miller, K.
    Wen, W.
    Kowalski, M.
    Lynch, S.
    Dain, B.
    Munera, C.
    Ripa, S.
    JOURNAL OF PAIN, 2013, 14 (04): : S80 - S80
  • [26] Sustained improvement in general health-related quality life and work productivity in patients with moderate to severe psoriasis treated with guselkumab: 3-year data from clinical trial VOYAGE 2
    Reich, K.
    Gordon, K. B.
    Foley, P.
    Lomaga, M.
    Han, C.
    Song, M.
    Shen, Y. -K.
    Radtke, M. A.
    Wu, J. J.
    Armstrong, A.
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2019, 81 (04) : AB280 - AB280
  • [27] Long-term effectiveness and tolerability of apremilast in patients with moderate-to-severe plaque psoriasis: A 5-year multicentre retrospective study-IL PSO (Italian landscape psoriasis)
    Gargiulo, L.
    Ibba, L.
    Malagoli, P.
    Amoruso, F.
    Balato, A.
    Bardazzi, F.
    Burlando, M.
    Carrera, C. G.
    Dapavo, P.
    Dini, V.
    Gaiani, F. M.
    Girolomoni, G.
    Guarneri, C.
    Lasagni, C.
    Loconsole, F.
    Marzano, A. V.
    Maurelli, M.
    Megna, M.
    Travaglini, M.
    Costanzo, A.
    Narcisi, A.
    JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2024, 38 (11) : e946 - e949
  • [28] Long-term quality of life outcomes from a phase 4 study of tildrakizumab in patients with moderate-to-severe plaque psoriasis in a real-world setting
    Bhatia, Neal
    Heim, Jayme
    Vasquez, J. Gabriel
    Bhutani, Tina
    Schenkel, Brad
    Gogineni, Ranga
    Koo, John
    JOURNAL OF DERMATOLOGICAL TREATMENT, 2024, 35 (01)
  • [29] Long-term efficacy and safety of tildrakizumab in Japanese patients with moderate to severe plaque psoriasis: Results from a 5-year extension of a phase 3 study (reSURFACE 1)
    Imafuku, Shinichi
    Nakagawa, Hidemi
    Igarashi, Atsuyuki
    Morita, Akimichi
    Okubo, Yukari
    Sano, Shigetoshi
    Tada, Yayoi
    Nemoto, Osamu
    Rozzo, Stephen J.
    Kawamura, Masaki
    Ohtsuki, Mamitaro
    JOURNAL OF DERMATOLOGY, 2021, 48 (06): : 844 - 852
  • [30] Long-term, durable, absolute Psoriasis Area and Severity Index and health-related quality of life improvements with risankizumab treatment: a post hoc integrated analysis of patients with moderate-to-severe plaque psoriasis
    Gooderham, M.
    Pinter, A.
    Ferris, L. K.
    Warren, R. B.
    Zhan, T.
    Zeng, J.
    Soliman, A. M.
    Kaufmann, C.
    Kaplan, B.
    Photowala, H.
    Strober, B.
    JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2022, 36 (06) : 855 - 865
12345